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Background: Since the late ‘90s, infliximab (Remicade®) is being used successfully
to treat patients with several non-infectious immune mediated inflammatory diseases
(IMIDs). In recent years, infliximab biosimilars, including Remsima® were introduced in
clinical practice.
Aim: To investigate the interchangeability of Remicade® (originator infliximab)
and its biosimilar Remsima® in patients with rare immune-mediated inflammatory
diseases (IMIDs).
Methods: This two-phased prospective open label observational study was designed
to monitor the transition from Remicade® to Remsima® in patients with rare IMIDs.
All included patients were followed during the first 2 years. The primary endpoint
was the demonstration of non-difference in quality of life and therapeutic efficacy, as
measured by parameters including a safety monitoring program, physicians perception
of disease activity (PPDA) and patient self-reported outcomes (PSROs). Secondary
outcomes included routine blood analysis, pre-infusion serum drug concentration values
and anti-drug antibody formation.
Results: Forty eight patients treated with Remicade® were switched to Remsima®
in June-July 2016 and subsequently monitored during the first 2 years. The
group consisted of patients with sarcoidosis (n = 17), Behçet’s disease (n =
12), non-infectious uveitis (n = 11), and other diagnoses (n = 8). There were no
significant differences in PPDA, PSROs, clinical and laboratory assessments and
pre-infusion serum drug concentrations between the groups. De novo anti-drug
antibodies were observed in two patients. Seven patients with sarcoidosis and five
with another diagnosis developed a significant disease relapse (n = 7) or adverse
events (n = 5) within 2 years; 10 of these patients discontinued Remsima® treatment,
one withdrew from the study and one received additional corticosteroid therapy.
Xue et al. Recurrent Disease Activity on Remsima®
Conclusions: We observed no significant differences in PSROs, PPDA and laboratory
parameters after treatment was switched from Remicade® to Remsima®. However,
disease relapse or serious events were observed in 12 out of 48 patients when
treatment was switched from Remicade® to Remsima®. The choice to switch anti-TNF
alpha biologics in patients with rare IMIDs, particularly in sarcoidosis, requires well-
considered decision-making and accurate monitoring due to a possibly higher incidence
of disease worsening.
Keywords: infliximab, Remicade®, Remsima®, CTP 13, biosimilar, rare or orphan immune-mediated inflammatory
diseases (IMIDs), anti-TNF-alpha, fucosylation
INTRODUCTION
Remicade R© (Janssen Biologics, Leiden, Netherlands) was the
first tumor necrosis factor alpha (TNF-alpha)-blocking chimeric
monoclonal antibody (the originator infliximab) to be approved
by the US Food and Drug Administration (FDA). It was
approved in 1998 and later approved by the European Medicines
Agency (EMA) in 1999 as a new therapy for Crohn’s disease
(CD) (1–3). Anti-TNF-alpha therapy rapidly proved to be
an efficacious, albeit expensive, treatment for other immune-
mediated inflammatory diseases (IMIDs), such as refractory
rheumatoid arthritis (RA), ankylosing spondylitis (SpA) and
psoriasis (1–3).
Several biosimilars for infliximab have been introduced in
the past few years. Remsima R© (Celltrion Healthcare, Budapest,
Hungary) was the first infliximab biosimilar to be authorized
in Europe and was authorized in the USA by the FDA in
2016 for the same therapeutic indications as those approved for
Remicade R© (4, 5).
Prescribing infliximab biosimilars may represent a good
solution for controlling costs. Introducing Remsima R© instead
of Remicade R© as a treatment for IMIDs was estimated to
represent a potential savings of 2·89 million to 33·80 million
euros in five European countries (Germany, The UK, Italy, the
Netherlands and Belgium) over a 1-year period (2015) based
on a budget impact model. In 2017, the average drug cost
per patient per year was approximately £10.070 for Remicade R©
compared with £9,063 for Remsima R©, and these costs are
declining further (6, 7).
A few studies have demonstrated that among patients
switched from Remicade R© to Remsima R©, Remsima R© was either
non-different or non-inferior with regard for efficacy and safety
among patients with IMIDs who were followed during the first 2
years after switching (6, 8–11). However, non-inferiority studies
have been performed only among patients with RA, SpA and IBD,
all of which are relatively common IMIDs. Since 2000, infliximab
has also been increasingly and successfully used in many rare
IMIDs, including non-infectious uveitis, (neuro)sarcoidosis and
Behçet’s disease (BD) (12–15). To our knowledge, there are no
published data on the use of Remsima R© as a treatment for these
rare diseases. This gap in the knowledge of the field leads to a
certain reluctance to prescribe this biosimilar in rare IMIDs even
though the prescription of Remsima R© instead of Remicade R©
would significantly diminish treatment costs per patient.
In this study, we evaluated whether the earlier
interchangeability of Remicade R© and Remsima R© reported
in patients with more common non-infectious IMIDs would also
apply to a cohort of patients with rare IMIDs.
MATERIALS AND METHODS
Study Design and Patients
Given the drug costs of biologics and financial budgets, the
department of Clinical Immunology at Erasmus University
Medical Center in Rotterdam, The Netherlands, switched
48 patients with rare refractory IMIDs from Remicade R© to
Remsima R© (Table 1). In June 2016, Remicade R© was replaced by
Remsima R© as the standard first choice product in all current and
future patients on infliximab. Patients were informed by written
information letter and personal communication prior to being
switched from Remicade R© to Remsima R©.
Monitoring was designed as a two-phase prospective
observational study and approved by the local medical ethical
committee (MEC-2016-302).
Patients with rare IMIDs were selected from the outpatient
clinic of clinical immunology at the Erasmus University Medical
Center (EMC, Rotterdam, The Netherlands). Initially, 50 patients
from the outpatient clinic of clinical immunology were eligible
for inclusion. The patients had received off-label infliximab
treatment because of previously refractory disease and/or
unacceptable side effects to standard immunosuppressive agents.
Informed consent for off-label Remicade R© and Remsima R©
treatment was obtained from all patients when decided to start
infliximab therapy. Two of these patients discontinued infliximab
treatment prior to the switch due to clinical remission. Forty-
eight patients were included in our monitoring program. The
median age at the start of the study population (at the start of
the study, June 2016) was 51 years old (SD± 14·7 years old). The
group consisted of patients with sarcoidosis (n = 17), BD (n =
12), non-infectious uveitis (n= 11), and other diagnoses (n= 8),
as summarized in Table 1.
The inclusion criteria were as follows:
– Stable disease and infliximab treatment for at least 6 months,
– Previous compliance was unremarkable, and
– If applicable, concomitant therapy was not altered for at least
4 weeks prior to inclusion.
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TABLE 1 | Patients baseline characteristics (n = 48).
AGE (YEAR)
Mean ± SD 51 ± 14·7
Gender
Male 46% (n = 22/48)
Female 54% (n = 26/48)
DIAGNOSES
Sarcoidosis (n = 17)
Behçet’s disease (n = 12)
Non-infectious uveitis (n = 11)
Other diagnoses (n = 8)
One systemic sclerosis
One relapsing polychondritis
One leucocytoclastic vasculitis
Two orbital pseudotumor
One granulomatous common variable Immunodeficiency
(CVID)
One pyoderma gangrenosum
One spondyloarthritis and vasculitis
DURATION OF Remicade® TREATMENT (MONTHS)
Mean ± SD 48 ± 38
FOLLOW-UP TIME (MONTHS) AFTER SWITCHING
[Range] 24 [23–25]
After June 1, 2016, all included patients were switched to
Remsima R© at their first upcoming treatment date. Phase I
indicated an intensive monitoring period during the first 6
months of the study (the monitoring phase). The patients were
examined and interviewed by the monitoring investigators and
by the treating doctors at three time points: at inclusion/baseline
(before the first infusionwith Remsima R©) and 3months after and
6 months after switching. Thereafter, the patients were further
routinely examined by their treating doctors as part of their usual
care during the follow-up phase (phase II).
The follow-ups performed during the follow-up phase in the
first 2 years were conducted at six time points. During phase I,
those were on the day of first infusion with Remsima R© (baseline
score) and three and six months later, and during phase II, those
were at 12, 18, and 34 months after the day of inclusion.
Discontinuation of therapy for reasons related to the patient’s
preference, medical contraindication for continuing biosimilar or
total discontinuity of infliximab treatment due to disease activity
was permitted at any time point.
Study Outcomes and Assessments
Safety Monitoring Program
Safety monitoring was implemented prior to every treatment
infusion at the day care clinic, which is compulsory according to
local guidelines. The monitoring consisted of a description of the
incidence and type of adverse events, the incidence and type of
disease worsening and any decline in physical, psychological and
social functions.
Physicians Perception of Disease Activity (PPDA)
Objective disease activity was regularly monitored clinically by
physicians at the outpatient clinic of the department of Clinical
Immunology. During the follow-up period, the physicians were
invited to provide descriptive data (remission/stable/active)
about disease activity related to the clinical performance
of each patient during the past 3 or 6 months. The
clinical data obtained in each patient at different time points
were provided by the same physician to ensure minimal
interobserver variation. The incidence of disease worsening
and (adverse) events were calculated based on the full
analysis set.
Patient Self-Reported Outcomes (PSROs)
PSROs were measured at the three time points (at initiation and
after 3 and 6 months) through interviews with patients using
the RAND-36 health survey and self-reported disease activity
questionnaires. RAND-36 is the Dutch version of the health
questionnaire SF-36, which measures the quality of life during
the last 4 weeks by nine health dimensions (16).
Laboratory Analyses
The secondary outcomes included routine blood assessments, the
pre-infusion drug concentration and the presence of anti-drug
antibodies (ADA) in serum. Standard clinical blood assessments
were conducted prior to every infusion according to the
department’s protocol for infusions with infliximab. Parameters
such as CRP, hemoglobulin, platelets, leucocytes, creatinine,
ASAT and ALATwere verified by a physician. Physician approval
was needed to start each infliximab infusion.
The infliximab concentration and levels of anti-drug
antibodies were analyzed using the pre-infusion serum samples
collected at the following three time points: baseline and after 3
and 6 months. Commercially available ELISA-based test systems
(MabTrack infliximab) produced by Sanquin (Amsterdam,
the Netherlands) were used for measuring infliximab serum
concentrations and the levels of anti-drug antibodies. The test
systems were used according to the manufacturer’s instructions
without modification. Cut-off levels of < 0·5 mcg/ml have
been proposed in the literature, and a level of 2·8 mcg/ml was
considered functional (17). Therefore, pre-infusion infliximab
concentrations below 3 mcg/ml and 0·5 mcg/ml were considered
low and very low drug concentrations, respectively (17, 18).
ADA analyses were performed only in patients with low
drug concentrations.
Statistical Analyses
The Wilcoxon one-sample test was applied for comparisons of
non-normal distributed descriptive data. A log transformation
was applied for all clinical blood parameters, and the
mean differences were determined in comparison with
the baseline mean. A p < 0·05 was considered to indicate
a significant difference. A Bonferroni post hoc test was
applied to calculate the adjusted p-value for correction for
multiple testing.
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RESULTS
Safety Monitoring Program
All patients were treated with infliximab for at least 6 months
and had shown a stable and lasting clinical response on
Remicade R©. The mean duration of Remicade R© treatment
prior to the switch was 48 months, and the average follow-
up time after switch was 24 months (range, 23 to 25
months) (Table 1). See Supplementary Tables 1–3 for additional
background information of patients with sarcoidosis, Behçet’s
disease and uveitis.
All included patients were carefully examined by physicians
prior to every treatment infusion and on the clinic day to
ensure drug safety. In total, 22 events were observed until
June 30st, 2018; these included one death, two significant
adverse events, two ADA formation, 7 disease relapses or
progression of pre-existing symptoms, two non-related events
and eight mild adverse events. Thirteen of these patients received
either different treatments (n = 12) or additional therapy (n
= 1) (Figure 1; Table 2). Figure 2 demonstrates the survival
curve of Remsima R© in the whole group and the three largest
groups (sarcoidosis, uveitis and Behçet’s disease) in course
of time.
In the first 3 months, two patients on Remsima R© switched
back to Remicade R©, one because of progression of pre-
existing headache and one because of new-onset angioedema.
After this patient switched back to Remicade R©, angioedema
did not reoccur. In the patient suffering from headache,
the complaints persisted while on Remicade R© treatment and
therefore discontinued further infliximab therapy. Eventually,
this patient was evaluated by a neurologist and diagnosed with
medication-induced headache, which improved after cessation of
painkiller use.
Between 3 and 6 months, another five patients had changed
back from Remsima R© to Remicade R© because of relapse of
the underlying sarcoidosis (n = 2), worsening of pre-existing
polyneuropathy (n = 2) or severe nausea (n = 1). After re-
initiation of Remicade R©, remission was achieved in the patients
with disease relapse or worsening of polyneuropathy. Nausea did
not improve after the initiation of Remicade R©. These complaints
were probably not disease- or treatment-related but were instead
likely caused by diaphragmatic hernia.
During the same period, in one patient with granulomatous
disease as a result of common variable immune deficiency
(CVID), rituximab was introduced because of disease
progression while on Remsima R© treatment. One patient
with sarcoidosis was diagnosed with proximal bilateral muscle
weakness in the lower extremities caused by hypocalcaemia; this
was not related to disease activity or Remsima R© treatment, and
her proximal lower extremity weakness improved after calcium
supplementation. However, she discontinued the infliximab due
to unexplained clinical symptoms at that moment and de novo
ADA formation with low serum drug levels.
Additional short-term glucocorticosteroid treatment was
administered to one patient with frequent flares of relapsing
polychondritis during Remicade R© treatment which was
comparable after switching to Remsima R©.
Twelve months after the start of the study, one additional
patient showed a flare of uveitis while on Remsima R© and
was switched back to Remicade R© with beneficial effects.
Moreover, one patient with a history of recurrent life-threatening
neurosarcoidosis had discontinued infliximab treatment and was
switched to adalimumab due to de novo ADA formation to
prevent recurrent disease. One patient with SpA and vacuities
was diagnosed with new-onset interstitial lung disease while on
Remsima R© during the follow-up and was thereafter effectively
treated with rituximab therapy.
Finally, there were two cases of withdrawal, including one
case of death. This patient suffered from severe therapy-
refractory neurosarcoidosis and showed side effects to previously
administered disease modifying anti-rheumatic drugs, and he
had a history of recurrent aspiration pneumonia; this latter
association was probably related to the cause of death. The other
patient had chosen to receive further treatment in a hospital near
her residency.
Additionally, eight cases with suspected infusion-related mild
adverse events, including skin involvement (n= 4), ankle oedema
(n = 2), or arthralgia (n = 2), were reported by patients during
the follow-up [data not shown].
All signs of relapse of disease activity and significant adverse
events were objectively verified and carefully examined by
specialized physicians. The cases were broadly discussed with
the involved clinical immunologists, neurologists and clinical
pharmacologists of Erasmus UniversityMedical Center to find an
explanation. Furthermore, the findings were discussed with the
supplier, who informed the authorities (LAREB). At that time,
no evident association or any explanation between Remsima R©
and the reported cases was available. Furthermore, the patient
suffering from headaches, as well as the patient reporting nausea
had persisting symptoms after they were switched back on
Remicade R©, making Remsima R© “failure” rather unlikely.
Follow-up is ongoing with 41 patients and 34 of these patients
remain on Remsima R© treatment.
Physicians Perception of Disease Activity
(PPDA)
The incidence of increased disease activity scores (n = 7) and
significant adverse events (n = 5) were 14·6% (7/48) and 10·4%
(5/48), respectively, based on the full analysis set (n = 48)
(Figure 3). Supplementary Tables 4, 5, respectively demonstrate
the disease activity index measured with Behcet’s disease current
activity form (19) and Uveitis disease activity index (20) during
the first 6 months.
Patient Self-Reported Outcomes (PSROs)
None of the nine measured quality of life aspects (RAND-
36) showed significant differences from baseline among the
biosimilar-treated patients during the first 6months (all p> 0·05)
(Table 3). The largest difference measured between baseline and
6months was found in themental health evaluation. The baseline
score ± standard deviation was 74·8 ± 20·0, and the 6th month
score ± standard deviation was 77·5 ± 22·1. The calculated
Z-score change was −1·970 (p = 0·05). Physical functioning
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FIGURE 1 | Flowchart study population.
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TABLE 2 | Safety monitoring during the first 24 months.
Patient Gender Diagnoses Event Treatment modification
(Time point)
Outcome after treatment
modification
Death (n = 1)
1. M Neurosarcoidosis Probable recurrent aspiration
pneumonia
(6th month)
Significant adverse events (n = 2)
2. F Sarcoidosis Angioedema e·c·i· Switched back to Remicade®
(3rd month)
No more events with
angioedema
3. F SpA and
vasculitis
New onset Interstitial lung
disease
Changed over to rituximab
(12th month)
Stable on rituximab
De novo ADA formation (n = 2)
4. F Sarcoidosis Proximal muscle weakness in
lower limbs +ADA
Discontinued with infliximab
(6th month)
Muscle weakness caused by
hypocalcaemia and improved
after calcium supplementation
5. M NeuroBehçet ADA formation without clinical
worsening
Changed over to adalimumab
(9th month)
Stable on adalimumab
Disease relapses (n = 5)
6. M Neurosarcoidosis Generalized seizures due to
disease relapse
Switched back to Remicade®
(6th month)
Stable on Remicade®
7. F Granulomatous
CVID
Generalized seizures due to
disease relapse
Changed over to rituximab
(6th month)
Stable on rituximab
8. M Neurosarcoidosis Reactivation underlying disease Switched back to Remicade®
(6th month)
Stable on Remicade®
9. F Relapsing
polychondritis
Reactivation underlying disease Additional corticosteroid
(5th month)
Disease in remission after
short-term corticosteroid
10. F Uveitis Flare uveitis Switched back to Remicade®
(11th month)
Stable on Remicade®
Progression of pre-existing symptoms (n = 2)
11. M Sarcoidosis Worsening of polyneuropathy Switched back to Remicade®
(4th month)
Improvements of symptoms on
Remicade®
12. M Neurosarcoidosis Worsening of polyneuropathy Switched back to Remicade®
(5th month)
Improvements of symptoms on
Remicade®
Other events (n = 2)
13. F Sarcoidosis Worsening of headache 1. Switched back to Remicade®
(3rd month)
Discontinued with infliximab
(5th month)
Diagnosed with
medication-induced headache,
which improved after cessation
of painkiller overuse
14 F Uveitis Severe nausea Switched back to Remicade®
(5th month)
Persistent nausea caused by
diaphragmatic hernia
Mild adverse events (n = 8): Skin involvements (n = 4), Edema (n = 2), Arthralgia (n = 2)
demonstrated the smallest Z-score change (−0·18) during the
first 6 months, from 65·2 ± 27·4 (baseline ±SD) to 67·3 ± 25·7
(6thmonth± SD), p= 0·86. However, a further disease subgroup
analysis was unreliable due to the limited number of patients
in subgroups.
Laboratory Analyses
The 95% CI of the mean differences between the groups
for all clinical parameters crossed zero with an overall p >
0·05 (Table 3). The hemoglobulin level obtained during the
first 3 months of Remsima R© therapy was significantly higher
than the baseline level. The mean difference (baseline vs. 3rd
month) was −0·008 mmol/l with 95% CI [0·01; 0·014], p =
0·019. The difference was, however, no longer significant after
correction for multiple testing (adjusted p < 0·001 needed
for significance).
Low pre-infusion drug concentrations were found in 20
patients at the time of inclusion, but this finding was not always
clinically related to disease activity (Table 3). Six of these patients
showed pre-existing ADAs in clinically quiescent disease. All
of these patients had a very low drug concentration below 0·5
mcg/ml. Four additional patients developed a low pre-infusion
drug concentration during the first 2 years after switching and
showed no disease relapse.De novoADA formation was observed
in two additional patients without clinical worsening caused by
ADA formation at that moment. However, both patients had
a fragile clinical condition. Therefore, it was initially decided
to discontinue further infliximab treatment in both patients to
prevent severe outcomes.
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FIGURE 2 | Survival curve of three largest group on Remsima®.
FIGURE 3 | Physicians perception of disease activity on Remsima®.
DISCUSSION
This prospective observational monitoring study demonstrated
that the differences in PSRO’s and other laboratory
parameters between Remsima R© and Remicade R© treatment
groups containing patients with rare IMIDs were non-
significant. However, 41% of sarcoidosis patients had
significantly increased disease activity or adverse events
mainly during the first year after the switch that led to a
therapeutic intervention.
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TABLE 3 | Results patient self-reported outcomes and clinical blood assessments.
Baseline
(n = 48)
3rd month
(n = 46)
6th month
(n = 38)
6th month vs. Baseline
RAND-36 dimensions Mean (±SD) Mean (±SD) Mean (±SD) Z-score change P-value
Physical functioning 65·2 (±27·4) 60·5 (±32·8) 67·3 (±25·7) −0·18 0·86
Social functioning 64·4 (±29·7) 69·1 (±29·0) 68·1 (±29·1) −0·80 0·42
Role limiting (physical) 40·3 (±36·5) 42·2 (±32·9) 46·1 (±32·3) −1·20 0·23
Role limiting (emotional) 71·5 (±33·6) 74·5 (±32·5) 76·3 (±28·9) −0·93 0·35
Mental health 74·8 (±20·0) 75·5 (±23·4) 77·5 (±22·1) −1·97 0·05*
Vitality 53·5 (±25·8) 51·1 (±22·8) 52·1 (±25·9) −0·36 0·72
Pain 65·2 (±29·2) 66·6 (±28·5) 63·7 (±30·1) −0·33 0·74
General health perception 40·2 (±23·5) 36·4 (±22·7) 36·0 (±26·6) −1·16 0·25
Health change 3·1 (±1·1) 3·3 (±1·1) 3·0 (±1·1) −0·72 0·47
Laboratorial parameters Mean (±SD) Mean (±SD) Mean (±SD) Mean difference [95%CI] P-value
LogCRP 0·51 (±0·61) 0·47 (±0·61) 0·47 (±0·65) 0·040 [−0·094; 0·174] 0·55
LogHb 0·91 (±0·04)$* 0·91 (±0·05)$* 0·91 (±0·05) −0·005 [−0·014; 0·005] 0·31
LogPlatelets 2·40 (±0·12) 2·42 (±0·12) 2·41 (±0·12) −0·012 [−0·036; 0·012] 0·32
LogLeucocytes 0·81 (±0·12) 0·84 (±0·13) 0·83 (±0·12) −0·018 [−0·041; 0·005] 0·13
LogCreatinine 1·92 (±0·12) 1·91 (±0·13) 1·90 (±0·14) 0·018 [−0·011; 0·047] 0·22
LogASAT 1·41 (±0·15) 1·42 (±0·13) 1·42 (±0·15) −0·005 [−0·059; 0·048] 0·84
LogALAT 1·39 (±0·22) 1·39 (±0·21) 1·40 (±0·22) −0·016 [−0·074; 0·041] 0·57
Drug concentration and ADA’s n/N (%) n/N (%) n/N (%)
Concentration < 3 mcg/ml# 20/48 (41·7) 23/48 (47·9) 24/48 (50·0)
Concentration < 0·5 mcg/ml 13/20 (65·0) 10/23 (43·5) 10/24 (41·7)
Presence of ADA’s 6/13 (46·2) 7/10 (70·0) 8/10 (80·0)
$LogHb (3rd month vs. baseline): Mean difference [95% CI] was −0·008 [−0·014; −0·001] with P = 0·019.
* and bold values: Both p-values are no more significant after correction for multiple testing using Bonferroni post hoc test.
#Based on full analysis set.
In the present study, 34 out of 48 patients with rare IMIDs
(70%) who switched from Remicade R© to Remsima R© maintained
this treatment for at least 2 years. Fourteen major events were
observed during this period, and these led to alterations in
therapy. Previous studies have demonstrated that a safe transition
to Remsima R© from Remicade R© is possible and that Remsima R©
is non-inferior to Remicade R© in common IMIDs, including RA,
IBD and SpA. In those studies, approximately 60% of the patients
with common IMIDs maintained Remsima R© treatment without
major or severe adverse events (8, 10, 21, 22).
In contrast, when we evaluated our results regarding the
transition from Remicade R© to Remsima R© in rare IMIDs with
those obtained in other reports on patients with more prevalent
IMIDs, we found that a substantial number of patients who
were diagnosed with granuloma, including (neuro)sarcoidosis,
had therapy failure or exacerbation of neurological symptoms
that could not be explained by pre-infusion drug levels. These
patients could safely return to Remicade R© without altering the
infusion dosage or interval. In-depth discussions with various
specialists initially provided no direct clue about the relevant
disease activity.
However, over time, more data have become available
supporting a hypothesis to explain the differences observed
between Remicade R© and Remsima R© in the predominantly
granulomatous disorders evaluated in this study.
The NOR-SWITCH study demonstrated that there was an
almost significant difference for recurrent disease in CD, which
is also proposed to be a granulomatous disorder, after patients
were switched from Remicade R© to Remsima R©. These results are
especially interesting when compared with those obtained for
ulcerative colitis (UC) in the same study (8).
Several studies have described the differences in the
glycosylation profile between Remicade R© and its biosimilars,
such as Remsima R©/Inflectra R© and Renflexis R©/Flixabi R©; these
differences could potentially lead to differential biological actions
(23, 24). With regard for infliximab action, the terminal glycan
composition of the Fc region plays a critical role in the binding
affinity of infliximab to the Fcγ receptor (FcγR) on immune cells,
such as natural killer (NK) cells and CD8+ lymphocytes. This
binding interaction is essential to induce antibody-dependent
cell-mediated cytotoxicity (ADCC) and apoptosis in target cells.
In vitro data have shown that there is a significant difference
in the afucosylated glycoform level in Remicade R© (10·0%)
compared to Remsima R© (6·2%) (p < 0·001). This variation
in afucosylation levels subsequently leads to lower levels of
the FcyR-binding affinity of Remsima R© (77·0%) compared to
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Remicade R© (100·9%) and substantially lower ADCC activity
for Remsima R© (50·3%) compared to Remicade R© (99·8%) (p <
0·001) (23, 24).
Hence, we postulate that the differences in afucosylation
between Remicade R© and Remsima R© might be associated with
the different biological activities of Remsima R© in patients with
granulomatous diseases, such as sarcoidosis.
This hypothesis is further supported by the finding that
sarcoidosis relapses in patients on etanercept (ETN) therapy (25–
27). ETN does not bind to membrane-expressed TNF and is
therefore unable to induce cytotoxicity by CD8+ and NK cells
(28–30). This effect is thought to be necessary to induce a clinical
effect in diseases characterized by granuloma formation (28–
30). If an afucosylated Fc fragment is also necessary to induce a
therapeutic response in non-infectious uveitis is unknown, this
finding would be of interest because ETN therapy is associated
with relapse of uveitis (31).
We are not aware of other studies that describe differences in
clinical efficacies and side effects after switching fromRemicade R©
to Remsima R© among patients with rare IMIDs, in particular
sarcoidosis. However, it is important to note that we did not
had a control arm treated with the originator. Therefore, we
could not rule out the possibility that the recurrent disease
activity might be a part of the course of disease rather due
to the switch to Remicade R©. We could only include a limited
number of patients in our study resulting in a weak statistical
power in the subgroups. Moreover, in this study, our objective
evaluation of disease activity was based solely on physician
perception and may therefore have been affected by differences
in interpersonal interpretations.
This is the result of the heterogeneity of the diseases entities
included in the study, as well as the lack of standardized
activity scores for many of those rare IMIDs. Registries for
monitoring patients with rare IMIDs may contribute to draw
stronger conclusions.
In conclusion, the implementation of Remsima R© treatment
among rare immune diseases in particular (neuro)sarcoidosis
patients previously treated with Remicade R© requires a
well-considered decision-making and intensive monitoring
due to a possibly higher incidence of disease worsening or
exacerbation of (neurologic) symptoms. Remicade R© and its
biosimilar Remsima R© might exert different biological actions
in certain disease conditions such as sarcoidosis, and these
might be related to differences in fucose content of the Fc
fragment. Further studies should be implemented to investigate
the biological activity of Remsima R©, especially in granulomatous
diseases such as sarcoidosis. In general, switching from one
biologic to another requires careful monitoring to prevent the
patient from unwanted side effects or relapse of the disease.
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